San Diego, CA, United States of America

Jon Kuehler

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 9.6

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2015-2022

where 'Filed Patents' based on already Granted Patents

8 patents (USPTO):

Title: Jon Kuehler: Innovator in Cancer Treatment

Introduction

Jon Kuehler is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cancer treatment. With a total of 8 patents to his name, Kuehler's work is recognized for its potential impact on medical science.

Latest Patents

Kuehler's latest patents include innovative compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. These compounds, described in his patent titled "MTA-cooperative PRMT5 inhibitors," are designed to be used in pharmaceutical compositions aimed at treating cancer. The invention details methods of use for these compounds, highlighting their importance in advancing cancer therapies.

Career Highlights

Throughout his career, Jon Kuehler has worked with notable companies in the pharmaceutical industry. He has been associated with Takeda Pharmaceutical Company Limited and Mirati Therapeutics, Inc., where he has contributed to groundbreaking research and development efforts. His expertise in the field has positioned him as a key player in the innovation of cancer treatment solutions.

Collaborations

Kuehler has collaborated with several talented individuals in his field, including Anthony Ivetac and Benjamin Jones. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in research.

Conclusion

Jon Kuehler's contributions to the field of pharmaceuticals, particularly in cancer treatment, underscore his role as an influential inventor. His innovative patents and collaborations reflect a commitment to improving medical outcomes through scientific advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…